name CEO growth to revenue My second announce to afternoon. quarter is Zynex. XXXX of quarter and Good Thomas positive Sandgaard, and our excited another of net President earnings income. I'm call. Welcome
share. $X.XX and it XX% was same second compared last quarter income, in of XXth quarter Our were second impact companies, year, last quarter Adjusted with the revenue also the we've increase to of our quarter of net $XX.X in to of company. year. Similar to quarter also COVID-XX. the compared the seen It million per straight the positive quarterly XX% history. an increase million, highest EBITDA of revenue the was was history earnings It the and was highest of diluted many $X.X second was the company's the for an
up year-over-year and June. and of The while where in second growth quarter first we which growth in saw we May the year, last quarter substantially in growth were only XX% than in was than order XX% second orders QX, saw XXX% we in year-over-year, came quarter, the throughout lower XX% the April XX% higher momentum but
in end continued sales see once increase have in the footprint July, our strength our and in The order pain. to increase continues non-addictive progress speaks growth. has expand prescribers, of States. in force them we month in strength to non-opioid sales the continue United prescribe to force for relationship the month for many solutions same geographic expanding with an our across need patients again to growth prescription volumes expect to order the the The we and the as investment We
We continue sales than of reps. more XXX sales have as aggressively today surpassed add and reps, to
recruiting helped in unemployment the rates by been efforts Our due have to surge to candidates a related increased COVID-XX.
sales hires regards second-half at these skyrocketed, in positions of the significant our the expect growth which for approximately reps We to strong Applications our basis. in helpful Revenue expect in new improving over have growth its compared of the XX% we have year-over-year office year-end. quarter in come. the XX% to to orders on sales corporate a XXXX to grew also a first In for increase and to quarter, is workforce. provide XX force, years XXX in XXX over second and productivity open into and continued September, by our obviously
quarter NexWave is a business catalog now. model the devices also from in revenue XX% prior periods, in used slowdown in even typically Remember, helpful Our our received are derived is approximately of we they earlier. the temporary quarter, a be therapy We device, actually as force In by monthly consumed and supplies the was for like our plan X,XXX and basis. clinics patients our introduced devices, second popular for for years this opener orders billing sales for great products, our that U.S. support, effort cetera. back regular on an into get clinics to and a brands products a obtain order all the traction physical low in to over most et on prescriptions door all more the initiative
remains previously all of raw for uninterrupted our and our interruption, without secured non-Chinese continue supply operations components sources and chain second materials. we as Our
the The level the to shelf, get to this pain of have of ability abuse. issue four on us thousands to XX patient placed off on first pain. to obtain use Currently, opioid our to practice our impact to die be of our for hand reached prescription months the epidemic internal a finished and strength components as top and on we devastating technology of opioids, line keep prescription. serious orders months have in-house In for opioid with of for ship the increasingly we're the XX once treating when to continues critical in yearly it's immediately over addition, months defense It's several where working vendors and tens products a to assembly, has of country, a to due the in patients materials. physicians
literally We to that develop aware of technology effects. side has our physicians more continue tools no make to
pain rehabilitation Our the the very products rehabilitation management, product still and for of position and industry. for out stand puts as strong stroke management in a products the for us markets. incontinence The for our in treatment in InWave device rehabilitation, best some pain NeuroMove the NexWave
We also area both in of revenue-generating for well a unmet product pain as divisions, huge existing great our our continue see our as potential volume blood to management, potential for monitor.
non-invasive probably As patient's in for balance hospitals centers. know, FDA intended we most to managed our get CMXXXX and earlier to volume year. fluid monitor CMXXXX is blood clearance The surgical of already this monitor monitor fluid a and you
we'll in fewer team the this surgeries, the one July, safer hiring next and typically recovery biggest display of to as initially detect until well and mortality; that to to surgeries unmet less ICUs, the loss, and few substantial today. bleeding believe out and quarters. occur. rooms as hospitals serious blood complications We expect during lead needs common operating building in for are today will began We product difficult continue complications, this division and where target rooms We internal
I over in Moorhead, production. will quarter, and end and resources, the CFO. the Dan expect quality, human We more functions to than the dozen common turn third our the by also now from call main people we're business employed recruiting, have a of the short-term, obviously this leveraging payroll, subsets, accounting, division to